問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



E-DA Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 824Kaohsiung CityKaohsiung Yanchao

Recruiting Trial

95Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

259Cases

2022-12-01 - 2026-07-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-07-31 - 2014-09-30

Phase III

An open-label, randomized, multi-center, parallel grouped clinical trial comparing the efficacy and safety of Mylan's Insulin Glargine and Lantus® for patients with type 2 diabetes.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Mylan′s Insulin Glargine

Participate Sites
7Sites

Terminated7Sites

2014-11-11 - 2018-11-26

Phase III

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

  • Condition/Disease

    Type II Diabetes

  • Test Drug

    Canagliflozin

Participate Sites
8Sites

Terminated8Sites

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

  • Condition/Disease

    major adverse cardiovascular event, MACE

  • Test Drug

    Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2015-08-17 - 2017-11-30

Phase III

A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily administration of TAK-438 20 mg compared to Lansoprazole 30 mg in the Treatment of Subjects with Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

侯明志
Taipei Veterans General Hospital

Digestive System Department

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2011-03-01 - 2012-12-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-02-15 - 2012-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2009-05-30 - 2010-10-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-05-30 - 2010-10-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 17 18 19 20 21 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB